{"id":7674,"date":"2025-03-11T18:58:19","date_gmt":"2025-03-11T17:58:19","guid":{"rendered":"https:\/\/www.isrec.ch\/?post_type=recherche&p=7674"},"modified":"2026-04-21T10:00:10","modified_gmt":"2026-04-21T08:00:10","slug":"blood-cancer-prof-riether-unibe-dr-wehrli-inselspital","status":"publish","type":"recherche","link":"https:\/\/www.isrec.ch\/en\/research\/blood-cancer-prof-riether-unibe-dr-wehrli-inselspital\/","title":{"rendered":"Blood cancer<\/strong> – Prof. Carsten Riether (UNIBE) and Dr. Marc Wehrli (INSEL)"},"content":{"rendered":"\n

Enhancing CAR-T Cell therapy for refractory multiple myeloma<\/h2>\n\n\n

In December 2024, this \u201callocated fund\u201d, amounting to CHF 100\u2019000, was granted to Prof. Carsten Riether and Dr. Marc Wehrli for one year.<\/h5>\n\n\n

Chimeric antigen receptor (CAR) T cells represent a significant advancement in cancer immunotherapy, especially for blood cancers. This treatment involves genetically modifying a patient’s T cells to express engineered receptors that more effectively eliminate cancer cells. Recent advances focus on enhancing the effectiveness of CAR-T cell therapy for patients with relapsed or refractory multiple myeloma (MM).<\/p>\n\n\n\n

MM is a type of blood cancer that originates from malignant plasma cells in the bone marrow. Despite recent advancements in treatments, MM remains a challenging disease due to its recurrent nature. B-cell maturation antigen (BCMA) targeting CAR-T cell therapy has demonstrated effectiveness, but its benefits are often short-lived.<\/p>\n\n\n\n

This research seeks to identify specific surface proteins that could enhance the performance of BCMA CAR T cells. We will be conducting an analysis of blood samples from 20 patients. This group includes 10 patients who are either experiencing progressive or stable disease following CAR-T therapy and 10 patients who have achieved a complete response. Blood samples will be collected at various intervals. Our aim is to isolate anti-BCMA CAR-T cells from these samples to perform a CRISPR screening. This screening will target surface proteins that have been identified through advanced techniques in single-cell RNA sequencing. Ultimately, this study aims to identify surface proteins that enhance the persistence of CAR-T cells in multiple myeloma. This identification will lay the foundation for the next generation of BCMA CAR-T cell therapies, which could significantly improve patient outcomes.<\/p>\n","protected":false},"featured_media":0,"template":"","cat-recherche":[117],"class_list":["post-7674","recherche","type-recherche","status-publish","hentry","cat-recherche-projects"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t